...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pharmacological sciences. >QT PROD ACT: Database Construction for the Evaluation of the Risk of QT Interval Prolongation by Drugs in Japan
【24h】

QT PROD ACT: Database Construction for the Evaluation of the Risk of QT Interval Prolongation by Drugs in Japan

机译：QT PROD ACT：在日本评估药物QT间隔延长风险的数据库构建

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The main reason for the withdrawal of drugs from the market is the appearance of the side effects of prolongation of the QT interval and the resultant polymorphic ventricular tachycardia called torsade de pointes (TdP). Several structurally unrelated drugs such as terfenadine, astemizol, and cisapride have been removed from the Japanese market because of this drug-induced TdP. Recent progress in molecular biology and electrophysiology has led to a better understanding of the ionic mechanism of drug-induced QT prolongation. It is considered that drug-induced inhibition of the rapid component of the delayed rectifier K~+ current (I_(Kr)), and therefore hERG (human ether-a-go-go related gene) channels, is the major cause of the acquired long-QT syndrome.
机译：药物退出市场的主要原因是QT间期延长和由此产生的多形性室性心动过速（称为扭转性扭转性室性心动过速）的副作用的出现。由于这种药物诱导的TdP，几种结构上不相关的药物，例如特非那定，阿司咪唑和西沙必利已经从日本市场撤出。分子生物学和电生理学的最新进展使人们对药物诱导的QT延长的离子机制有了更好的了解。据认为，药物诱导的对延迟整流器K〜+电流（I_（Kr））的快速成分的抑制，以及因此对hERG（人类以太相关基因）通道的抑制，是导致这种情况的主要原因。获得性长QT综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号